Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-G-Universal-IFU.pdf.
Released November 25, 2025
When 83-year-old Richard Martin was diagnosed with pancreatic cancer in 2024, he underwent 22 rounds of chemotherapy followed by radiation.
He wasn’t a candidate for surgery because of his tumor’s proximity to a vein, but a new therapy platform being utilized at Moffitt Cancer Center offered him another treatment option.